Literature DB >> 6538075

Optimizing metoclopramide control of cisplatin-induced emesis.

B R Meyer, M Lewin, D E Drayer, M Pasmantier, L Lonski, M M Reidenberg.   

Abstract

Using an original high-pressure liquid chromatographic assay, we measured serum levels of metoclopramide and defined a concentration-response relationship for metoclopramide control of cisplatin-induced emesis. Using a metoclopramide regimen of 2 mg/kg body weight intravenously every 2 hours for four doses, we found that serum levels greater than 850 ng/mL immediately before the third dose were associated with complete control of emesis (less than three episodes) in 78% of patients and partial control (three to five episodes) in 18%. No patient with levels less than 850 ng/mL had complete control of emesis; only 42% had partial control (p less than 0.001). Increases in dosage for patients with low levels and poor responses improved control in four of five patients. Elderly patients had drug levels similar to those of young patients but had fewer episodes of emesis (p = 0.044), suggesting that elderly patients have increased sensitivity to this drug. The metoclopramide dose can be raised up to 2.75 mg/kg with an improvement in emetic control in patients who have an inadequate response to doses of 2 mg/kg and no toxicity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538075     DOI: 10.7326/0003-4819-100-3-393

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  16 in total

1.  Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis.

Authors:  J M Brechot; J P Dupeyron; C Delattre; C Chastang; J P Laaban; J Rochemaure
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs.

Authors:  D Cunningham; M Soukop; N L Gilchrist; G J Forrest; A Hepplestone; I T Calder; C S McArdle; A W Hutcheon; S B Kaye
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-23

3.  High-dose metoclopramide by infusion: a double-blind study of plasma concentration-effect relationships in patients receiving cancer chemotherapy.

Authors:  W B Taylor; J M Simpson; D N Bateman
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Population analysis of the pharmacokinetic variability of high-dose metoclopramide in cancer patients.

Authors:  J Grevel; B Whiting; A W Kelman; W B Taylor; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

5.  The relationship between steady state metoclopramide levels and control of emesis during treatment with cis-platinum.

Authors:  D J Kerr; J Graham; R G Blackie; E McGovern; A W Kelman; D Cunningham; S B Kaye
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

6.  Does parenteral magnesium sulfate have an antiemetic effect during chemotherapy with cis-platinum?

Authors:  P E Ballmer; W H Reinhart
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  A single dose pharmacokinetic study of Gastrobid Continus and Maxolon in the perioperative period.

Authors:  T H Madej; F R Ellis; I Tring
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

Review 8.  Pharmacokinetics of high-dose metoclopramide in cancer patients.

Authors:  E M McGovern; J Grevel; S M Bryson
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

Review 9.  Optimum management of nausea and vomiting in cancer chemotherapy.

Authors:  P L Triozzi; J Laszlo
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

10.  Examination of the correlation of serum metoclopramide levels with antiemetic efficacy in patients receiving cisplatin.

Authors:  S M Grunberg; J E McDermed; L Bernstein; J L Cohen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.